Table of Contents
Islet cell transplantation represents one of the most significant advances in the treatment of type 1 diabetes, offering hope to individuals who struggle with severe hypoglycemia and unstable blood sugar control. This innovative procedure involves extracting insulin-producing islet cells from a donor pancreas and infusing them into a patient’s liver, where they can begin producing insulin naturally. While the concept is straightforward, the reality of islet cell transplantation is complex, with longevity being one of the most critical factors determining long-term success.
Understanding how long these transplanted cells remain functional is essential for patients considering this treatment option and for researchers working to improve outcomes. Long-term outcome data from national cohorts confirm durable graft survival beyond 20 years in a subset of recipients, though results vary significantly among individuals. The journey of islet cell transplantation from an experimental procedure to an FDA-approved therapy has been marked by continuous refinement and innovation, making it increasingly viable for carefully selected patients.
The Evolution of Islet Cell Transplantation
The development of the Edmonton Protocol for islet transplantation in 2000 revolutionized T1D treatment and offered a glimpse at a cure for the disease. This groundbreaking protocol established standardized procedures for islet isolation, transplantation techniques, and immunosuppressive therapy that dramatically improved success rates. Before the Edmonton Protocol, success rates for islet transplantation were disappointingly low, with only about 8-9% of patients achieving insulin independence.
The Edmonton Protocol introduced several key innovations that transformed outcomes. It called for transplanting large quantities of islet cells—approximately 10,000 islet equivalents per kilogram of body weight—often requiring islets from multiple donor pancreases. The protocol also implemented a steroid-free immunosuppression regimen, which was crucial because steroids had been shown to be toxic to transplanted islet cells. According to CITR 11th and multicenter trials, insulin independence at one year now approaches 70% in appropriately immunosuppressed recipients, representing a remarkable improvement over earlier attempts.
In 2022, the 20-year follow-up findings of islet cell transplantation demonstrated the long-term safety of islet cell transplantation despite chronic immunosuppression. This milestone study provided crucial evidence that islet transplantation could be both effective and safe over extended periods, addressing concerns about the long-term risks associated with immunosuppressive medications.
Current Success Rates and Longevity Data
The longevity of islet cell transplants has improved substantially over the past two decades, though it remains variable among recipients. Understanding the timeline of graft function helps set realistic expectations for patients and guides clinical decision-making.
Short-Term Outcomes
A Phase 3 clinical trial found that infusing islets into the portal vein of forty-eight patients with brittle T1DM led to 87.5% achieving an HbA1c <7.0 with no severe hypoglycemic events at 1-year post-transplant and 71% of patients sustaining these criteria by 2 years. These impressive short-term results demonstrate that islet transplantation can effectively restore glycemic control and eliminate dangerous hypoglycemic episodes in the majority of carefully selected patients.
At 1 year, approximately 59% of all transplant recipients were free of severe hypoglycemic events and maintained hemoglobin A1c (HbA1c) level of ≤6.5%, and 91% of all recipients were free of severe hypoglycemic episodes at 1 year. The near-universal protection from severe hypoglycemia represents one of the most significant benefits of islet transplantation, even for patients who do not achieve complete insulin independence.
Medium-Term Graft Survival
In a large cohort study, the median follow-up time was 7.4 years, with 90% patient survival and a median graft survival of 5.9 years. This data from the Edmonton Protocol cohort provides valuable insights into the durability of islet transplants beyond the initial years following transplantation.
Ten years after islet transplantation, median HbA1c was 7.2% versus 8.0% before transplantation, and seventeen of 23 (73.9%) recipients were free of severe hypoglycemia. These findings from the Swiss-French GRAGIL Network demonstrate that even when complete insulin independence is not maintained, islet transplants continue to provide meaningful clinical benefits for many years.
Long-Term Durability
The most encouraging data comes from long-term follow-up studies that track patients for decades after transplantation. Kaplan–Meier estimates indicated graft survival rates of 86% at 1 year, 65% at 5 years, 47% at 10 years, 47% at 15 years, and 40% at 20 years. This Italian single-center study provides the longest follow-up data available, demonstrating that a significant proportion of patients maintain functional grafts for two decades.
The Miami group reported a 90% 20-year patient survival in 49 patients, with marked reduction in diabetes-related mortality in comparison with diabetes registry data. This finding suggests that islet transplantation may not only improve quality of life but also extend survival in patients with severe type 1 diabetes.
Long-term outcomes demonstrated in the NIH-supported Clinical Islet Transplantation (CIT) Consortium ITA trials, with follow-up for 8.3 years, included 56% of patients with graft survival and 49% with HbA1c <7.0%. These results from rigorously conducted clinical trials confirm that many patients maintain excellent glycemic control nearly a decade after transplantation.
Critical Factors Influencing Transplant Longevity
The duration of islet cell transplant function depends on multiple interconnected factors, ranging from immunological responses to the quality of the transplanted cells themselves. Understanding these variables is crucial for optimizing outcomes and developing strategies to extend graft survival.
Immune Response and Rejection Mechanisms
The immune system poses the most significant challenge to long-term islet graft survival. When foreign islet cells are introduced into the body, the immune system recognizes them as non-self and mounts an attack designed to eliminate them. This immune response occurs through multiple pathways, including both cellular and antibody-mediated mechanisms.
Alloimmune rejection occurs when the recipient’s immune system recognizes donor-specific antigens on the transplanted islets. T-cells, particularly CD8+ cytotoxic T-cells and CD4+ helper T-cells, play central roles in this process. These cells can directly attack and destroy transplanted islet cells or coordinate broader immune responses that lead to graft dysfunction and eventual failure.
Additionally, patients with type 1 diabetes have an underlying autoimmune condition that originally destroyed their own pancreatic beta cells. This autoimmune response can recur after transplantation, targeting the newly transplanted islets even though they come from a different individual. The combination of alloimmune and autoimmune responses creates a particularly challenging environment for transplanted islets.
Inflammation also plays a critical role in early graft loss. The instant blood-mediated inflammatory reaction (IBMIR) occurs immediately when islets come into contact with blood in the portal vein. This reaction involves activation of the coagulation and complement systems, leading to thrombosis and inflammation that can destroy a significant portion of transplanted islets within the first few hours to days after transplantation.
Immunosuppressive Therapy
To prevent rejection, all islet transplant recipients must take immunosuppressive medications, typically for life. Because such transplantations occur in the allogeneic setting, recipients require immunosuppressive therapy, and this chronic and systemic adjuvant treatment can lead to toxicity, increased risks of infection and tumor development, and ultimately a decreased quality of life for patients.
The choice of immunosuppressive regimen significantly impacts transplant outcomes. Modern protocols typically include induction therapy with T-cell depleting antibodies, followed by maintenance immunosuppression with combinations of drugs such as tacrolimus, sirolimus, or mycophenolate mofetil. It has been recognized that the more potent induction therapy with T-cell depleting antibodies not only allows for successful single donor islet transplants but also improved long term outcomes.
However, immunosuppressive medications present a double-edged sword. While they prevent rejection, some of these drugs can be directly toxic to islet cells or impair their function. Calcineurin inhibitors like tacrolimus, while effective at preventing rejection, can negatively affect beta cell function and insulin secretion. Balancing adequate immunosuppression to prevent rejection while minimizing drug toxicity to the islets themselves remains an ongoing challenge.
Donor-Recipient Compatibility
The degree of immunological matching between donor and recipient influences transplant success and longevity. Human leukocyte antigen (HLA) matching, which is routinely performed for solid organ transplants, also plays a role in islet transplantation outcomes. Better HLA matching generally correlates with reduced immune responses and potentially longer graft survival.
ABO blood type compatibility is essential, as mismatched blood types can lead to hyperacute rejection mediated by preformed antibodies. Additionally, screening for donor-specific antibodies (DSA) before transplantation helps identify recipients at higher risk for antibody-mediated rejection.
The presence of pre-existing antibodies against donor antigens, whether from previous transplants, blood transfusions, or pregnancies, can significantly compromise graft survival. Sensitized patients with high levels of circulating antibodies face greater challenges in finding compatible donors and maintaining long-term graft function.
Quality and Quantity of Transplanted Islets
The health, viability, and quantity of islet cells at the time of transplantation critically influence both immediate engraftment and long-term function. Analysis of 1,210 islet recipients from 39 centers found a highly significant linear inverse relationship between primary graft function at 1 month after the last infusion and 5-year incidence of graft failure, highlighting the importance of successful early engraftment for long-term outcomes.
Islet isolation is a complex process that can damage cells and reduce their viability. The pancreas must be obtained from deceased donors and processed within a limited timeframe to preserve islet quality. During isolation, the pancreas is digested with enzymes to separate islets from the surrounding exocrine tissue, then purified through density gradient centrifugation. Each step in this process can stress the islets and reduce the number of viable, functional cells available for transplantation.
A functional β-cell mass of ≥40% of normal was a strong predictor of sustained insulin independence and long-term outcome, emphasizing that transplanting adequate numbers of high-quality islets is essential for achieving durable insulin independence. This often requires islets from multiple donor pancreases, which compounds the challenge of donor organ scarcity.
Islet quality assessment before transplantation includes evaluating cell viability, purity, and functional capacity. Islets that have been damaged during isolation or preservation may fail to engraft properly or may have shortened survival after transplantation. Advanced assessment techniques help identify high-quality islet preparations more likely to result in successful long-term outcomes.
Transplantation Site Factors
The liver, specifically the portal vein, has become the standard site for islet transplantation, but it presents several challenges that can limit graft longevity. Portal vein-specific factors including low oxygen tension and the instant blood-mediated inflammatory reaction are detrimental to initial engraftment and long-term function.
The liver environment is relatively hypoxic compared to the native pancreas, and islet cells are particularly sensitive to oxygen deprivation. This low oxygen tension can impair islet function and survival, especially during the critical early engraftment period before adequate vascularization is established. Additionally, exposure to high concentrations of immunosuppressive drugs that pass through the liver may contribute to islet toxicity.
Despite these limitations, alternative transplantation sites explored in preclinical and early clinical studies have not yet proven superior to the liver. Researchers continue investigating other potential sites, including the omentum, subcutaneous space, and muscle tissue, seeking locations that might provide better oxygenation, easier monitoring, or reduced immune responses.
Metabolic Demand and Graft Stress
The metabolic demands placed on transplanted islets can influence their longevity. Factors such as obesity, insulin resistance, and poor glycemic control before transplantation can increase the workload on transplanted islets, potentially leading to earlier exhaustion and graft failure. Recipients who maintain healthy body weight, follow appropriate dietary guidelines, and manage other aspects of their metabolic health may experience better long-term graft function.
Glucotoxicity and lipotoxicity—damage caused by chronically elevated glucose and lipid levels—can impair islet function over time. Even after successful transplantation, maintaining good metabolic control helps protect the transplanted islets from these harmful effects and may extend their functional lifespan.
Innovative Approaches to Extend Graft Longevity
Researchers and clinicians are actively developing and testing new strategies to overcome the limitations of current islet transplantation protocols and extend graft survival. These innovations span multiple areas, from cell source alternatives to immune protection strategies.
Stem Cell-Derived Islets
One of the most promising developments in recent years has been the generation of insulin-producing cells from pluripotent stem cells. Preliminary results of ongoing clinical trials suggest that the transplantation of stem cell–derived β-cells can consistently restore insulin independence in immunosuppressed recipients with type 1 diabetes, representing a potential solution to the chronic shortage of donor organs.
Vertex Pharmaceuticals initiated a phase 1/2 clinical trial (VX-880) in 2021, with cells transplanted intraportally into the liver under full-dose immunosuppression, and by June 2024, 12 patients had been dosed; 11 of 12 had marked reduction or complete insulin independence. These remarkable results demonstrate that stem cell-derived islets can function comparably to donor-derived islets in restoring insulin production.
In 2024–2025, the first autologous iPSC-derived islet transplants were reported in China, with a landmark case describing a young adult with type 1 diabetes achieving insulin independence following infusion of patient-specific iPSC-derived islets. Autologous approaches using a patient’s own cells to generate islets could potentially eliminate the need for immunosuppression, dramatically improving the risk-benefit profile of the procedure.
Stem cell-derived islets offer several potential advantages beyond addressing donor scarcity. They can be produced in standardized, controlled conditions, potentially resulting in more consistent quality compared to islets isolated from deceased donors. Manufacturing processes can be optimized to generate large numbers of high-quality islets, and cells can be thoroughly tested before transplantation to ensure safety and functionality.
Encapsulation Technologies
Pancreatic islet encapsulation has been explored as a strategy to address immune rejection issues in islet transplantation, and significant advancements have been made in the design and functionality of encapsulation devices, enhancing the viability and performance of transplanted islets.
Encapsulation involves surrounding islet cells with a protective barrier that allows nutrients, oxygen, and insulin to pass through while blocking immune cells and antibodies. This approach could potentially eliminate or greatly reduce the need for systemic immunosuppression, addressing one of the major limitations of current islet transplantation protocols.
Key advancements include the development of more biocompatible materials, improved microencapsulation techniques, the incorporation of immunomodulatory agents, and innovative oxygenation strategies. Modern encapsulation devices are designed to minimize foreign body responses while maximizing islet survival and function.
However, certain challenges remain, such as material degradation, managing the immune response, ensuring adequate nutrient and oxygen diffusion, scalability and manufacturing, and maintaining the functional longevity of the implanted cells. Overcoming these obstacles is essential for encapsulation to become a clinically viable approach for widespread use.
Both microencapsulation (individual islets or small clusters) and macroencapsulation (larger devices containing many islets) strategies are being investigated. Each approach has distinct advantages and challenges regarding retrievability, oxygen diffusion, immune protection, and scalability for clinical application.
Immune Evasion Strategies
Genetic engineering approaches are being developed to create “immune-privileged” islet cells that can evade immune detection and destruction without requiring systemic immunosuppression. The CyT49 human embryonic stem cell line is genetically engineered to lack the beta-2 microglobulin gene, preventing the expression of major histocompatibility complex class I molecules, and to express a transgene encoding programmed death ligand 1 for protection against CD8+ cytotoxic T-cell attack, making it a promising candidate for cell-based therapies.
Sana has initiated the first-in-human trial of hypoimmune gene-edited stem-cell-derived islets, designed to evade immune rejection without systemic immunosuppression, and early 2025 reports document graft survival with insulin secretion in recipients not receiving maintenance immunosuppression, with follow-up of ~6 months, providing the first clinical demonstration of immune evasion strategies in β-cell replacement.
These early results are particularly exciting because they suggest that islet transplantation without chronic immunosuppression may be achievable. If successful in larger trials with longer follow-up, immune evasion strategies could transform islet transplantation from a treatment reserved for patients with severe, life-threatening diabetes complications to a therapy that could be offered much earlier in the disease course.
Xenotransplantation
Porcine (pig) islets represent another potential solution to the donor shortage problem. Pigs can be bred specifically for transplantation purposes, and their islets are similar enough to human islets to function effectively in regulating blood glucose. Recently, an encapsulated pig islet IND has been filed and approved for islet transplantation, and clinical results are expected to be released in the course of 2025.
Genetic modifications can be made to pig islets to reduce immune rejection and eliminate concerns about transmission of porcine viruses to human recipients. One major issue is the risk of transmitting porcine endogenous retroviruses from pigs to humans, although studies suggest minimal risk with genetically modified pigs. Combining xenotransplantation with encapsulation technology may provide the best approach for using pig islets clinically.
Optimized Immunosuppression Protocols
Continued refinement of immunosuppressive regimens aims to maximize graft protection while minimizing drug toxicity and side effects. Newer immunosuppressive agents with more targeted mechanisms of action and better safety profiles are being investigated. Belatacept, a selective T-cell costimulation blocker, has shown promise in some studies for maintaining islet function while potentially causing less nephrotoxicity than calcineurin inhibitors.
Personalized immunosuppression based on individual patient characteristics, immune monitoring, and graft function may allow for optimization of drug regimens over time. Some patients may be able to reduce immunosuppression levels while maintaining adequate graft protection, while others may require more intensive therapy.
Tolerance induction strategies aim to “teach” the recipient’s immune system to accept the transplanted islets as self, potentially allowing for eventual withdrawal of immunosuppression. While this remains an aspirational goal, research in this area continues with some promising preclinical results.
Improved Islet Isolation and Preservation
Outcome improvement over the last decade is attributed to both refinement of the production of islets from allogeneic donors and evolution in the management of the recipient, and in North America, the collaborative approach of the CIT has led to incremental improvements and standardization of the islet isolation procedure resulting in less failed isolations and higher Islet yields.
Advances in pancreas preservation, enzyme formulations for digestion, and purification techniques continue to improve the quality and quantity of islets obtained from each donor pancreas. Better preservation solutions and hypothermic or normothermic perfusion systems may extend the viable time between pancreas procurement and islet isolation, allowing for better coordination of the complex logistics involved.
Culture conditions for islets between isolation and transplantation are being optimized to promote islet recovery from the stress of isolation while maintaining viability and function. Some centers are exploring brief culture periods that may allow islets to “rest” and repair damage before transplantation.
Clinical Outcomes Beyond Insulin Independence
While insulin independence is often highlighted as the primary goal of islet transplantation, the procedure provides numerous other clinical benefits that significantly improve patient outcomes and quality of life, even when complete insulin independence is not achieved or maintained.
Protection from Severe Hypoglycemia
More recent studies corroborate findings showing a marked reduction of severe hypoglycemic events up to 10 years post-transplant. This represents perhaps the most important benefit for many patients, as severe hypoglycemia can be life-threatening and significantly impairs quality of life.
Patients with hypoglycemia unawareness—the inability to recognize when blood sugar is dropping dangerously low—face particular risks. Islet transplantation can restore hypoglycemia awareness and provide protection against severe episodes even when patients still require some exogenous insulin. This protective effect often persists even after insulin independence is lost, as even partial graft function can help stabilize blood glucose levels and prevent dangerous lows.
Improved Glycemic Control
Recent data indicate that restoration of insulin secretion after islet cell transplantation is associated with an improvement in quality of life, with a reduction in hypoglycemic episodes and potentially with a reduction in long-term diabetic complications. Better overall glucose control, as measured by HbA1c levels and time in target range, reduces the risk of developing or worsening diabetes-related complications affecting the eyes, kidneys, nerves, and cardiovascular system.
Even patients who require some insulin supplementation after transplantation typically achieve better glycemic control with lower glucose variability compared to their pre-transplant state. This more stable glucose control can reduce the burden of diabetes management and improve overall health outcomes.
Impact on Diabetic Complications
β-cell replacement therapy has been shown to ameliorate a decline in kidney function. For patients who receive islet transplantation after kidney transplantation (islet-after-kidney), the improved glycemic control can help protect the kidney graft and extend its survival.
Reductions in atherothrombotic risk profiles and fewer cardiovascular events have also been described, along with improved renal allograft longevity in IAK recipients and increased overall survival in selected cohorts. These broader health benefits extend beyond glucose control alone, suggesting that islet transplantation may positively impact multiple aspects of diabetes-related disease.
Quality of Life Improvements
Patients who undergo successful islet transplantation often report substantial improvements in quality of life, including reduced anxiety about hypoglycemia, greater flexibility in daily activities and meal timing, improved sleep quality, and enhanced overall well-being. The freedom from constant glucose monitoring and insulin dose calculations, even if temporary, can be profoundly meaningful for individuals who have lived with the demanding burden of type 1 diabetes management for years or decades.
For many patients, the psychological benefits of knowing they have functioning insulin-producing cells again, even if they still require some supplemental insulin, provides hope and improves their relationship with their disease. The reduction in diabetes-related distress and improved mental health outcomes are important considerations when evaluating the overall success of islet transplantation.
Regulatory Approval and Clinical Access
The clinical and scientific recognition of islet transplantation has been reinforced by regulatory milestones, including the 2023 FDA licensure of allogeneic islets (donislecel-jujn, Lantidra) in the United States. This historic approval marked the first time islet cells were licensed as a biological product in the United States, representing a major milestone in the field.
Health authorities in several countries have approved deceased donor islet transplantation for treating patients with type 1 diabetes and recurrent severe hypoglycemia. These regulatory approvals reflect the accumulation of substantial evidence demonstrating the safety and efficacy of islet transplantation for carefully selected patients.
However, access to islet transplantation remains limited due to several factors. The scarcity of donor pancreases means that only a small number of patients can receive this treatment each year. The procedure requires specialized expertise in islet isolation and transplantation, which is available only at select centers. Additionally, the need for lifelong immunosuppression means that islet transplantation is currently recommended primarily for patients with severe, life-threatening complications of diabetes that cannot be adequately managed with intensive insulin therapy and continuous glucose monitoring systems.
Patient Selection and Candidacy
Appropriate patient selection is crucial for optimizing outcomes and ensuring that the benefits of islet transplantation outweigh the risks for individual patients. Current indications for islet transplantation are relatively narrow, focusing on patients with the most severe manifestations of type 1 diabetes.
Primary Indications
Frequent and severe hypoglycemic events are the most common indication for islet transplantation, and other possible indications include clinical and emotional problems associated with the use of exogenous insulin therapy that are so severe as to be incapacitating. Patients with hypoglycemia unawareness who experience recurrent severe hypoglycemic episodes despite optimal medical management are considered ideal candidates.
Islet-after-kidney transplantation is an important option for patients with type 1 diabetes who have already undergone kidney transplantation for end-stage renal disease. Since these patients are already taking immunosuppressive medications to protect their kidney graft, adding islet transplantation does not introduce new immunosuppression-related risks and can provide substantial benefits in terms of glycemic control and protection from hypoglycemia.
Exclusion Criteria
Certain factors may exclude patients from consideration for islet transplantation. Significant obesity, very high insulin requirements, active infections, malignancy, and contraindications to immunosuppressive therapy all represent potential barriers. Patients must also demonstrate the ability and willingness to comply with complex post-transplant medication regimens and follow-up requirements.
Psychological evaluation is an important component of the selection process, as patients must understand the risks and benefits of the procedure and maintain realistic expectations about outcomes. The commitment required for lifelong immunosuppression and regular monitoring is substantial, and patient motivation and support systems are important predictors of success.
Challenges and Limitations
Despite significant progress, islet cell transplantation faces several persistent challenges that limit its widespread application and long-term success.
Donor Organ Shortage
The scarcity of organ donors poses a significant limitation to these procedures. The number of patients who could potentially benefit from islet transplantation far exceeds the available supply of donor pancreases. This shortage is compounded by the fact that many patients require islets from multiple donors to achieve insulin independence, further limiting the number of individuals who can be treated.
Pancreases used for islet isolation are typically those that have been declined for whole pancreas transplantation, and the quality of these organs can be variable. Improving pancreas procurement, preservation, and allocation systems could help maximize the utility of available organs, but fundamental limitations in donor supply will persist until alternative cell sources become widely available.
Immunosuppression Requirements and Risks
The requirement for lifelong immunosuppression remains one of the most significant limitations of current islet transplantation protocols. Immunosuppressive medications carry risks of infections, malignancies, kidney toxicity, metabolic effects, and other side effects that can significantly impact patient health and quality of life.
The risk-benefit calculation for islet transplantation must carefully weigh the benefits of improved glycemic control and protection from hypoglycemia against the risks associated with chronic immunosuppression. This is why current indications focus on patients with severe, life-threatening complications of diabetes where the benefits clearly outweigh the risks.
Gradual Graft Function Decline
Despite the marked progress in the field of clinical islet transplantation, the inability of this procedure to sustain long-term insulin independence warrants further developments. Even successful transplants typically show gradual decline in function over time, with many patients eventually requiring return to insulin therapy, albeit often at lower doses than before transplantation.
Understanding the mechanisms underlying this gradual loss of function—whether due to chronic rejection, islet exhaustion, recurrent autoimmunity, or other factors—is essential for developing strategies to extend graft longevity. Some patients maintain partial graft function for many years, continuing to derive clinical benefits even without complete insulin independence.
Technical and Logistical Complexity
Islet isolation is a technically demanding procedure that requires specialized equipment, expertise, and facilities. The process must be completed within a limited timeframe after pancreas procurement, requiring careful coordination between organ procurement organizations, islet isolation laboratories, and transplant centers. Not all pancreases yield sufficient numbers of high-quality islets for transplantation, and isolation failures represent a loss of precious donor resources.
The infrastructure required to support clinical islet transplantation programs is substantial, including Good Manufacturing Practice (GMP) facilities for islet processing, specialized personnel, and quality control systems. These requirements limit the number of centers capable of offering islet transplantation and contribute to the overall cost and complexity of the procedure.
The Future of Islet Cell Transplantation
The field of islet cell transplantation stands at an exciting juncture, with multiple promising developments converging to address current limitations and expand the potential of this therapy.
Unlimited Cell Sources
The development of stem cell-derived islets represents perhaps the most transformative advance on the horizon. These achievements amplified academic and industry efforts to generate pluripotent stem cell–derived β-cells through directed differentiation for β-cell replacement, and preliminary results of ongoing clinical trials suggest that the transplantation of stem cell–derived β-cells can consistently restore insulin independence in immunosuppressed recipients with type 1 diabetes.
If stem cell-derived islets prove to be safe, effective, and durable in larger trials with longer follow-up, they could eliminate the donor shortage problem entirely. Manufacturing scalability would allow production of sufficient islets to treat all patients who could benefit, potentially expanding indications to include earlier intervention in the disease course before severe complications develop.
Immunosuppression-Free Transplantation
Avoiding the risks of chronic immunosuppression represents the next frontier, and several strategies have entered or are approaching clinical investigation, including immune-isolating islets, engineering immune-privileged islet implantation sites, rendering islets immune evasive, and inducing immune tolerance in transplanted islets.
The combination of immune evasion strategies with stem cell-derived islets could create an ideal scenario: unlimited cell supply without the need for immunosuppression. This would fundamentally change the risk-benefit calculation for islet transplantation, potentially making it appropriate for a much broader patient population, including children and young adults early in their disease course.
Personalized Medicine Approaches
Advances in understanding individual patient factors that influence transplant outcomes may enable more personalized approaches to islet transplantation. Genetic profiling, immune monitoring, and biomarker analysis could help identify patients most likely to benefit from transplantation and guide individualized immunosuppression strategies.
Autologous iPSC-derived islets, created from a patient’s own cells, represent the ultimate personalized approach. While technical challenges remain, this strategy could eliminate both the donor shortage and immunosuppression requirements, offering the potential for a true cure for type 1 diabetes.
Integration with Diabetes Technology
The relationship between islet transplantation and diabetes technology continues to evolve. While some view these as competing approaches, they may actually be complementary. Patients with partial graft function might benefit from hybrid closed-loop insulin delivery systems that can work synergistically with endogenous insulin production to optimize glucose control.
Advanced continuous glucose monitoring systems can provide detailed data on graft function and glucose patterns, enabling more precise management of patients after transplantation. Integration of transplant monitoring with digital health platforms may improve long-term outcomes through better detection of graft dysfunction and optimization of immunosuppression.
Broader Clinical Applications
Once clinical islet transplantation has been successfully established, this treatment could even be offered to diabetic patients long before the onset of diabetic complications. As safety improves and immunosuppression requirements are reduced or eliminated, the indications for islet transplantation may expand significantly.
Earlier intervention could prevent the development of complications rather than simply managing them after they occur. This preventive approach could transform outcomes for people with type 1 diabetes, potentially allowing them to live complication-free lives with normal or near-normal glucose control.
Monitoring and Managing Transplant Recipients
Successful long-term outcomes after islet transplantation require careful monitoring and management of recipients. Regular follow-up includes assessment of graft function, monitoring for rejection, management of immunosuppression, and screening for complications.
Graft Function Assessment
C-peptide measurement is the primary method for assessing islet graft function. C-peptide is produced in equimolar amounts with insulin by beta cells, and its measurement provides a direct indication of endogenous insulin production. Fasting C-peptide levels and stimulated C-peptide responses to glucose or mixed meals help quantify the functional capacity of transplanted islets.
Continuous glucose monitoring provides detailed information about glucose patterns, variability, and time in target range. These metrics help assess the clinical impact of graft function on glycemic control and can detect early signs of graft dysfunction before complete failure occurs.
HbA1c levels provide a measure of average glucose control over the preceding 2-3 months and serve as an important outcome measure for assessing the overall effectiveness of islet transplantation in improving metabolic control.
Immunosuppression Management
Therapeutic drug monitoring of immunosuppressive medications ensures that levels remain within target ranges—high enough to prevent rejection but low enough to minimize toxicity. Dose adjustments may be needed based on drug levels, kidney function, side effects, and interactions with other medications.
Regular screening for complications of immunosuppression includes monitoring for infections, malignancies, kidney function, metabolic effects, and other potential adverse events. Early detection and management of these complications is essential for maintaining patient health and quality of life.
Rejection Surveillance
Monitoring for signs of rejection includes assessment of graft function, donor-specific antibody testing, and clinical evaluation. Unlike solid organ transplants, islet grafts cannot be easily biopsied, so rejection diagnosis relies primarily on functional decline and immunological markers.
Declining C-peptide levels, increasing insulin requirements, worsening glycemic control, and development of donor-specific antibodies may all indicate rejection. Early detection allows for intervention with increased immunosuppression or anti-rejection treatments that may preserve graft function.
Comparing Islet Transplantation to Other Treatment Options
Patients with severe type 1 diabetes have several treatment options to consider, each with distinct advantages and limitations.
Whole Pancreas Transplantation
Whole pancreas transplantation, often performed simultaneously with kidney transplantation in patients with end-stage renal disease, offers higher rates of long-term insulin independence compared to islet transplantation. However, it is a major surgical procedure with higher perioperative risks and complications. The choice between pancreas and islet transplantation depends on individual patient factors, including the presence of kidney disease, surgical risk, and patient preferences.
Advanced Insulin Delivery Systems
Hybrid closed-loop insulin delivery systems, which combine continuous glucose monitoring with automated insulin delivery, have dramatically improved outcomes for many people with type 1 diabetes. These systems can reduce hypoglycemia, improve time in target range, and decrease the burden of diabetes management. For many patients, these technologies provide excellent glycemic control without the risks associated with transplantation and immunosuppression.
However, even the most advanced insulin delivery systems cannot fully replicate physiologic insulin secretion, and some patients continue to experience problematic hypoglycemia or glucose variability despite optimal technology use. For these individuals, islet transplantation may offer benefits that cannot be achieved with technology alone.
Intensive Insulin Therapy
Multiple daily injections with careful carbohydrate counting and dose adjustment remain the foundation of diabetes management for most people with type 1 diabetes. While this approach can achieve good glycemic control in many patients, it requires constant vigilance and carries inherent risks of hypoglycemia and glucose variability.
For patients who can achieve their glycemic targets with intensive insulin therapy without excessive hypoglycemia or unacceptable burden, this remains the most appropriate treatment approach. Islet transplantation is reserved for those who cannot achieve adequate control despite optimal medical management.
Economic Considerations
The cost of islet cell transplantation is substantial, including expenses for organ procurement, islet isolation, the transplantation procedure, immunosuppressive medications, and long-term follow-up care. However, these costs must be weighed against the potential savings from reduced diabetes complications, fewer hospitalizations for severe hypoglycemia, and improved quality of life.
Economic analyses have suggested that for appropriately selected patients with severe hypoglycemia and high healthcare utilization, islet transplantation may be cost-effective over the long term. As the procedure becomes more standardized and outcomes continue to improve, the economic case for islet transplantation in selected populations strengthens.
Insurance coverage for islet transplantation varies by country and payer. The FDA approval of Lantidra in the United States has helped establish islet transplantation as a recognized therapy, which may facilitate broader insurance coverage and reimbursement.
Research Directions and Unanswered Questions
Despite remarkable progress, many important questions remain to be answered through ongoing and future research.
Mechanisms of Graft Loss
Better understanding of why islet grafts gradually lose function over time is essential for developing strategies to extend longevity. Is the primary problem chronic rejection, recurrent autoimmunity, islet exhaustion, or other factors? Advanced imaging techniques, biomarker discovery, and detailed immunological studies may provide insights into these mechanisms.
Optimal Timing of Intervention
When is the ideal time to perform islet transplantation? Should it be reserved only for patients with severe complications, or could earlier intervention prevent complications from developing? As safety improves, particularly if immunosuppression can be eliminated, this question will become increasingly important.
Combination Therapies
Could combining islet transplantation with other interventions—such as immunomodulatory therapies to prevent recurrent autoimmunity, or metabolic interventions to reduce islet stress—improve outcomes? Systematic investigation of combination approaches may identify synergistic strategies that enhance graft survival.
Predictive Biomarkers
Identifying biomarkers that predict which patients will have the best long-term outcomes could improve patient selection and allow for more personalized approaches. Similarly, biomarkers that detect early graft dysfunction before complete failure could enable timely interventions to preserve function.
Conclusion
The longevity of islet cell transplants has improved dramatically since the introduction of the Edmonton Protocol in 2000, with some patients maintaining graft function for two decades or more. However, significant variability exists among individuals, and many patients experience gradual decline in graft function over time, eventually requiring return to insulin therapy.
Multiple factors influence transplant longevity, including immune responses, the quality and quantity of transplanted islets, immunosuppressive regimens, donor-recipient compatibility, and transplantation site characteristics. Understanding and optimizing these factors has led to progressive improvements in outcomes, with current protocols achieving insulin independence in approximately 70% of patients at one year and meaningful clinical benefits persisting for many years in most recipients.
The field stands at an exciting crossroads, with transformative innovations on the horizon. Stem cell-derived islets promise to eliminate donor shortage limitations, while immune evasion strategies and encapsulation technologies may allow transplantation without chronic immunosuppression. These advances could fundamentally change the risk-benefit profile of islet transplantation, potentially making it appropriate for a much broader patient population.
For patients currently living with severe type 1 diabetes complicated by problematic hypoglycemia or extreme glucose variability despite optimal medical management, islet transplantation offers a proven treatment option that can dramatically improve quality of life and clinical outcomes. While challenges remain, particularly regarding long-term graft survival and the need for immunosuppression, the benefits for appropriately selected patients are substantial and well-documented.
As research continues to address current limitations and new technologies mature, islet cell transplantation is poised to play an increasingly important role in diabetes care. The ultimate goal—providing all people with type 1 diabetes access to safe, effective, durable beta cell replacement without the need for immunosuppression—may finally be within reach in the coming years.
For individuals considering islet transplantation, thorough discussion with experienced transplant teams is essential to understand whether this treatment is appropriate for their specific situation. The decision must carefully weigh the potential benefits against the risks and requirements of the procedure, taking into account individual medical history, diabetes complications, lifestyle factors, and personal goals.
To learn more about islet cell transplantation and whether you might be a candidate, consult with an endocrinologist or transplant center specializing in this procedure. Additional information is available from organizations such as the JDRF (Juvenile Diabetes Research Foundation), the American Diabetes Association, and the Collaborative Islet Transplant Registry, which maintains comprehensive data on islet transplantation outcomes worldwide.